致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註冊股本總額： ...

2026年1月30日晚，ST智知(603869.SH)发布了2025年度业绩预增公告，预计2025年度实现归属于母公司 所有者的净利润2,905万元到3,900万元，与上年同期相比，同比增加40.06%到88.04%。此次业绩预增， 得益于公司核心业务的稳健发力、新业务的快速突破以及内部管理的精细化升级，充分彰显了公司强劲 的发展韧性与核心竞争力。 报告期内，公司核心业务板块聚安网持续保持稳健增长态势，为整体业绩增长奠定了坚实基础。与此同 时，公司精准把握行业发展趋势，积极布局的企业数智化业务进展顺利，成功为公司贡献了新的利润增 长点，进一步丰富了公司盈利结构，拓宽了增长空间。 此次业绩预增，是公司深耕核心业务、积极拓展新赛道、持续推进精细化管理的综合成果，充分体现了 公司清晰的发展战略和强劲的经营韧性。 ...

公司核心业务板块聚安网继续保持稳健增长，为整体业绩奠定了坚实基础，企业数智化业务进展顺利， 为公司贡献了新的利润增长点。公司全面加强期间费用管控，在销售侧，结合业务结构调整，优化销售 团队结构，相关人工成本支出减少，同时基于业务规划，公司相应调整了研发结构，将研发资源聚焦聚 安网和企业数智化业务等核心业务领域，研发费用有所降低。此外公司加大回款及追偿力度，部分减值 损失得以冲回，进一步增强了财务稳健性。 格隆汇1月30日丨ST智知(603869.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司所 有者的净利润2,905万元到3,900万元，同比增加40.06%到88.04%。预计2025年年度实现归属于母公司所 有者的扣除非经常性损益后的净利润1,350万元到2,000万元，同比增加164.21%到195.13%。 ...

截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註 ...

Core Viewpoint - ST Zhizhi (603869.SH) announced that its wholly-owned subsidiary, New Intelligence Cognitive Data Service Co., Ltd., received a property tax refund for the year 2024, amounting to 3.4239 million yuan, which represents 16.51% of the company's audited net profit attributable to shareholders for the most recent fiscal year [1][1][1] Summary by Relevant Sections - Tax Reduction Approval: The company received approval from the Shanghai Pudong New Area Taxation Bureau for a 100% reduction in property tax for the period from January 1, 2024, to December 31, 2024 [1][1][1] - Refund Amount: The total property tax refund received on December 17, 2025, was 3.4239 million yuan [1][1][1] - Impact on Financials: The refund constitutes 16.51% of the company's latest audited net profit attributable to shareholders [1][1][1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | 0.001 HKD | | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/ ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註冊股本總額： HKD 500,000 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算 ...

Core Insights - ST Zhizhi (603869.SH) reported its Q3 2025 results on October 29, 2025, highlighting significant institutional investor interest in the company [1] Institutional Holdings - As of October 28, 2025, a total of 8 institutional investors disclosed their holdings in ST Zhizhi A-shares, with a combined shareholding of 324 million shares, representing 65.62% of the total share capital [1] - The institutional investors include notable entities such as Xin'ao Energy Supply Chain Co., Ltd., Tianjin Yienrui Investment Center (Limited Partnership), and others [1] - Compared to the previous quarter, the total institutional holding percentage increased by 1.35 percentage points [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註 ...

Financial Performance - For the six months ended June 30, 2025, the company reported revenue of RMB 743.0 million, a 3.3% increase from RMB 719.5 million in the same period last year[9]. - Adjusted gross profit for the same period was RMB 155.0 million, with an adjusted gross margin of 20.9%, down from 22.5% in the previous year[9][10]. - Adjusted net profit decreased to RMB 70.6 million, a decline of approximately 19.2% compared to RMB 87.3 million in the prior year[11]. - The company recorded a net profit of RMB 168.6 million, significantly up from RMB 23.6 million in the same period last year[10]. - The adjusted net profit margin for the first half of 2025 was 9.5%, down from 12.1% in the previous year[9]. - Adjusted operating profit was approximately RMB 102.5 million, down from RMB 123.0 million in the previous year, a decrease of about RMB 20.5 million attributed to reduced gross profit[16]. - The company reported a profit of RMB 168,620,000 for the six months ended June 30, 2025, compared to RMB 23,568,000 for the same period in 2024, representing a significant increase of 613%[93]. - Total comprehensive income for the period reached RMB 184,745,000, up from RMB 13,591,000 in the previous year, marking an increase of 1,262%[93]. Assets and Liabilities - As of June 30, 2025, total equity was approximately RMB 727.3 million, up from RMB 576.6 million as of December 31, 2024[17]. - Current assets were approximately RMB 1,019.7 million, a decrease of about RMB 79.4 million from RMB 1,099.1 million as of December 31, 2024, mainly due to a reduction in cash and cash equivalents[17]. - Current liabilities decreased significantly to approximately RMB 668.4 million from RMB 1,809.9 million as of December 31, 2024, primarily due to a reduction in convertible bonds[17]. - The company's cash and cash equivalents were approximately RMB 612.4 million as of June 30, 2025, down from RMB 714.1 million as of December 31, 2024[18]. - The total assets as of June 30, 2025, amounted to RMB 2,546,603 thousand, an increase from RMB 2,493,617 thousand as of June 30, 2024, showing a growth of about 2.1%[120][121]. - Total liabilities decreased to RMB 668,445,000 from RMB 1,809,925,000, a reduction of 63.0%[97]. - The net asset value increased to RMB 727,292,000 from RMB 576,623,000, representing an increase of 26.1%[97]. Shareholder Information - As of June 30, 2025, major shareholders hold significant stakes, with Hony Capital Fund V, L.P. owning 123,000,000 shares, representing approximately 89.01% of the company's issued shares[44]. - Hony Group Management Limited and its affiliates collectively hold 161,693,985 shares, accounting for about 117.01% of the company's issued shares[44]. - Liu Lu holds approximately 6.58% of the company's issued share capital through controlled entities[42]. - The company has a remaining share incentive plan authorization of 13,819,400 shares, equivalent to approximately 10% of the issued shares as of the report date[77]. Business Strategy and Operations - The company is focusing on enhancing its core competitiveness in the healthcare sector, particularly in the Yangtze River Delta region[11]. - The company is actively exploring innovative business models and increasing the application of new technologies such as artificial intelligence[11]. - The company aims to improve the quality of medical services while adapting to industry policy changes, including healthcare payment reforms[12]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[99]. Debt and Financing - The company has extended the maturity dates of convertible bonds with Yufeng Limited and Hony Capital Fund VIII to September 30, 2027, allowing for greater financial flexibility[13]. - The total principal amount of the convertible bonds issued to Hony Fund VIII is approximately HKD 773.9 million, with a similar extension of maturity to September 30, 2027[30]. - The company is focused on utilizing funds from the convertible bonds for future acquisitions and business expansion[46]. - The company has undergone several amendments to the terms of the convertible bonds, reflecting ongoing financial strategy adjustments[46]. Employee and Operational Costs - The total employee benefits expenditure for the six months ended June 30, 2025, was approximately RMB 244.0 million, compared to RMB 215.1 million for the same period in 2024[39]. - Employee costs for the six months ended June 30, 2025, were RMB 243,975 thousand, up from RMB 215,097 thousand in the same period last year, representing an increase of about 13.4%[125]. Regulatory and Compliance - The company is committed to regulatory compliance and standardized management practices in response to intensified market competition[12]. - The company has not used any derivative financial instruments to hedge foreign exchange risks and will consider appropriate hedging measures if necessary[34]. Dividends and Shareholder Returns - The company has decided not to declare any interim dividend for the six months ended June 30, 2025[38]. - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2025, consistent with the previous year[150]. Accounting and Reporting - The company adopted a new accounting policy to use Hong Kong dollars as its functional currency starting January 1, 2025, due to its operations being primarily denominated in HKD[110]. - The review report confirms that no matters were found that would indicate the interim financial report as of June 30, 2025, was not prepared in accordance with International Accounting Standard 34[163].